Menopausal Hormone Therapy in Gynecologic Cancer Survivors: A Review of the Evidence and Practice Recommendations.

Ekta Kapoor, Daniel Benrubi, Stephanie S Faubion

Journal: Clinical obstetrics and gynecology 2019;61(3):488-495

PMID: 29762148

Abstract

Gynecologic cancers are common in the United States and represent a significant health burden. Treatment of these cancers often causes premature cessation of ovarian function, with resultant symptoms that are often more severe than those associated with natural menopause. Hormone therapy is the most effective treatment for menopausal symptoms, but the decision-making process about its use can be complex for survivors of gynecologic cancer. In this review, we provide evidence-based recommendations about the use of hormone therapy after gynecologic cancer.

Address: Women's Health Clinic, Division of General Internal Medicine.; Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota.; Division of Gynecologic Oncology, Fox Chase Cancer Center at Temple University Hospital, Philadelphia, Pennsylvania.; Women's Health Clinic, Division of General Internal Medicine.

DOI: 10.1097/GRF.0000000000000381

Link outs

Free resources

Medical:

https://medlineplus.gov/menopause.html

Other Literature Sources:

https://scite.ai/reports/29762148

Subscription / membership required

Full Text Sources:

MeSH Terms: Cancer Survivors, Contraindications, Drug, Dyspareunia, Female, Genital Neoplasms, Female, Hormone Replacement Therapy, Hot Flashes, Humans, Menopause, Neoplasm Recurrence, Local, Patient Selection, Risk Assessment